


Pediatric ALL



Across

- 5.** TPMT testing is done to mitigate bone marrow suppression related to this agent
7. CNS-directed therapy is required for all patients even in the absence of CNS disease at diagnosis (True/False)
8. Number of phases of therapy required
13. Most common sign/symptom of ALL (50-60% of patients)
14. Anti-CD19/CD3 bispecific T-cell engager

15. Most common childhood cancer

16. This type of ALL requires 5 drug induction therapy

Down

- 1.** Number of drugs used to treat standard risk ALL during induction
2. Number of risk groups in pediatric ALL
3. Goal of therapy
4. Congenital condition with 10-20 fold increase risk for acute leukemia

6. Preferred corticosteroid for standard risk induction

9. Ploidy associated with favorable outcome

10. Most common translocation in childhood ALL ETV6-RUNX1 is also known as...

11. Strongest prognostic factor

12. This route of pegaspargase is associated with increased risk of HRS

17. NCI risk stratification for ALL includes WBC and _____ at diagnosis